APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nausea And Vomiting Treatment

Nausea and Vomiting Treatment also called Antiemetics. Antiemetics included aprepitant, diphenhydramine, granisetron, hydroxyzine, meclizine, ondansetron, prochlorperazine, promethazine, scopolamine, metoclopramide, trimethobenzamide, palonosetron, dolasetron, and thiethylperazine, etc.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Nausea and Vomiting Treatment also called Antiemetics. Antiemetics included aprepitant, diphenhydramine, granisetron, hydroxyzine, meclizine, ondansetron, prochlorperazine, promethazine, scopolamine, metoclopramide, trimethobenzamide, palonosetron, dolasetron, and thiethylperazine, etc.

Selected research

Market Outlook & Growth Opportunities

Global Nausea And Vomiting Treatment Market Outlook and Growth Opportunities 2026

20 December 2025197 pages

Choose your research edition.

Industry ResearchNausea And Vomiting Treatment Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Nausea And Vomiting Treatment Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Nausea And Vomiting Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nausea And Vomiting Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Nausea And Vomiting Treatment Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Nausea and Vomiting Treatment also called Antiemetics. Antiemetics included aprepitant, diphenhydramine, granisetron, hydroxyzine, meclizine, ondansetron, prochlorperazine, promethazine, scopolamine, metoclopramide, trimethobenzamide, palonosetron, dolasetron, and thiethylperazine, etc.

United States is the largest Nausea And Vomiting Treatment market with about 42% market share. Europe is follower, accounting for about 20% market share.Merck & Co. Inc. was the global greatest company in Nausea And Vomiting Treatment industry, with the market Share of 14% , followed by Helsinn Group, Unimed Pharmaceuticals (AbbVie Inc.), Kyowa Kirin, Sanofi, Qilu Pharma, Teva Pharmaceutical Industries Ltd., Taiji group, Novartis, Heron Therapeutics, Atnahs Pharma UK Limited, Mylan, Duchesnay, Tesaro.

This report provides an overview of the global Nausea And Vomiting Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Nausea And Vomiting Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nausea And Vomiting Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nausea And Vomiting Treatment market.

Nausea And Vomiting Treatment Segment by Company

Merck & Co. Inc.

Helsinn Group

Unimed Pharmaceuticals (AbbVie Inc.)

Kyowa Kirin

Sanofi

Qilu Pharma

Teva Pharmaceutical Industries Ltd.

Taiji group

Novartis

Heron Therapeutics

Atnahs Pharma UK Limited

Mylan

Duchesnay

Tesaro

Nausea And Vomiting Treatment Segment by Type

Serotonin Receptor Antagonist

Neurokinin NK1 Receptor Antagonist

Others

Nausea And Vomiting Treatment Segment by Application

CINV

PONV

Motion Sickness

Pregnancy

Others

Nausea And Vomiting Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nausea And Vomiting Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nausea And Vomiting Treatment key companies, revenue, market share, and recent developments.

3. To split the Nausea And Vomiting Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nausea And Vomiting Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nausea And Vomiting Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Nausea And Vomiting Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nausea And Vomiting Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nausea And Vomiting Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nausea And Vomiting Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nausea And Vomiting Treatment industry.

Chapter 3: Detailed analysis of Nausea And Vomiting Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nausea And Vomiting Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nausea And Vomiting Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nausea And Vomiting Treatment Industry Trends Table 2. Nausea And Vomiting Treatment Industry Drivers Table 3. Nausea And Vomiting Treatment Industry Opportunities and Challenges Table 4. Nausea And Vomiting Treatment Industry Restraints Table 5. Global Nausea And Vomiting Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nausea And Vomiting Treatment Revenue Share by Company (2021-2026) Table 7. Global Nausea And Vomiting Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nausea And Vomiting Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Nausea And Vomiting Treatment Company, Product Type & Application Table 10. Global Nausea And Vomiting Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nausea And Vomiting Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Serotonin Receptor Antagonist Table 15. Significant Companies of Neurokinin NK1 Receptor Antagonist Table 16. Significant Companies of Others Table 17. Global Nausea And Vomiting Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Nausea And Vomiting Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Nausea And Vomiting Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Nausea And Vomiting Treatment Sales Value Share by Type (2021-2026) Table 21. Global Nausea And Vomiting Treatment Sales Value Share by Type (2027-2032) Table 22. Significant Companies of CINV Table 23. Significant Companies of PONV Table 24. Significant Companies of Motion Sickness Table 25. Significant Companies of Pregnancy Table 26. Significant Companies of Others Table 27. Global Nausea And Vomiting Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Nausea And Vomiting Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Nausea And Vomiting Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Nausea And Vomiting Treatment Sales Value Share by Application (2021-2026) Table 31. Global Nausea And Vomiting Treatment Sales Value Share by Application (2027-2032) Table 32. Global Nausea And Vomiting Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Nausea And Vomiting Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Nausea And Vomiting Treatment Sales Value Share by Region (2021-2026) Table 35. Global Nausea And Vomiting Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Nausea And Vomiting Treatment Sales Value Share by Region (2027-2032) Table 37. Global Nausea And Vomiting Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Nausea And Vomiting Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Nausea And Vomiting Treatment Sales Value Market Share by Country (2021-2026) Table 40. Global Nausea And Vomiting Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Nausea And Vomiting Treatment Sales Value Market Share by Country (2027-2032) Table 42. Merck & Co. Inc. Company Information Table 43. Merck & Co. Inc. Business Overview Table 44. Merck & Co. Inc. Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Merck & Co. Inc. Nausea And Vomiting Treatment Product Portfolio Table 46. Merck & Co. Inc. Recent Development Table 47. Helsinn Group Company Information Table 48. Helsinn Group Business Overview Table 49. Helsinn Group Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Helsinn Group Nausea And Vomiting Treatment Product Portfolio Table 51. Helsinn Group Recent Development Table 52. Unimed Pharmaceuticals (AbbVie Inc.) Company Information Table 53. Unimed Pharmaceuticals (AbbVie Inc.) Business Overview Table 54. Unimed Pharmaceuticals (AbbVie Inc.) Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Unimed Pharmaceuticals (AbbVie Inc.) Nausea And Vomiting Treatment Product Portfolio Table 56. Unimed Pharmaceuticals (AbbVie Inc.) Recent Development Table 57. Kyowa Kirin Company Information Table 58. Kyowa Kirin Business Overview Table 59. Kyowa Kirin Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Kyowa Kirin Nausea And Vomiting Treatment Product Portfolio Table 61. Kyowa Kirin Recent Development Table 62. Sanofi Company Information Table 63. Sanofi Business Overview Table 64. Sanofi Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Sanofi Nausea And Vomiting Treatment Product Portfolio Table 66. Sanofi Recent Development Table 67. Qilu Pharma Company Information Table 68. Qilu Pharma Business Overview Table 69. Qilu Pharma Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Qilu Pharma Nausea And Vomiting Treatment Product Portfolio Table 71. Qilu Pharma Recent Development Table 72. Teva Pharmaceutical Industries Ltd. Company Information Table 73. Teva Pharmaceutical Industries Ltd. Business Overview Table 74. Teva Pharmaceutical Industries Ltd. Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Teva Pharmaceutical Industries Ltd. Nausea And Vomiting Treatment Product Portfolio Table 76. Teva Pharmaceutical Industries Ltd. Recent Development Table 77. Taiji group Company Information Table 78. Taiji group Business Overview Table 79. Taiji group Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Taiji group Nausea And Vomiting Treatment Product Portfolio Table 81. Taiji group Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Novartis Nausea And Vomiting Treatment Product Portfolio Table 86. Novartis Recent Development Table 87. Heron Therapeutics Company Information Table 88. Heron Therapeutics Business Overview Table 89. Heron Therapeutics Nausea And Vomiting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Heron Therapeutics Nausea And Vomiting Treatment Product Portfolio Table 91. Heron Therapeutics Recent Development Table 92. Atnahs Pharma UK Limited Company Information Table 93. Atnahs Pharma UK Limited Business Overview Table 94. Atnahs Pharma UK Limited Nausea And Vomiting Treatment Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Atnahs Pharma UK Limited Nausea And Vomiting Treatment Product Portfolio Table 96. Atnahs Pharma UK Limited Recent Development Table 97. Mylan Company Information Table 98. Mylan Business Overview Table 99. Mylan Nausea And Vomiting Treatment Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Mylan Nausea And Vomiting Treatment Product Portfolio Table 101. Mylan Recent Development Table 102. Duchesnay Company Information Table 103. Duchesnay Business Overview Table 104. Duchesnay Nausea And Vomiting Treatment Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. Duchesnay Nausea And Vomiting Treatment Product Portfolio Table 106. Duchesnay Recent Development Table 107. Tesaro Company Information Table 108. Tesaro Business Overview Table 109. Tesaro Nausea And Vomiting Treatment Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 110. Tesaro Nausea And Vomiting Treatment Product Portfolio Table 111. Tesaro Recent Development Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Nausea And Vomiting Treatment Product Image Figure 2. Global Nausea And Vomiting Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nausea And Vomiting Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Nausea And Vomiting Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Serotonin Receptor Antagonist Image Figure 8. Neurokinin NK1 Receptor Antagonist Image Figure 9. Others Image Figure 10. Global Nausea And Vomiting Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Nausea And Vomiting Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Nausea And Vomiting Treatment Sales Value Share by Type (2021-2032) Figure 13. CINV Image Figure 14. PONV Image Figure 15. Motion Sickness Image Figure 16. Pregnancy Image Figure 17. Others Image Figure 18. Global Nausea And Vomiting Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nausea And Vomiting Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Nausea And Vomiting Treatment Sales Value Share by Application (2021-2032) Figure 21. Global Nausea And Vomiting Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Nausea And Vomiting Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Nausea And Vomiting Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. North America Nausea And Vomiting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Nausea And Vomiting Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Nausea And Vomiting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Nausea And Vomiting Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Nausea And Vomiting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Nausea And Vomiting Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. South America Nausea And Vomiting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Nausea And Vomiting Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Nausea And Vomiting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Serotonin Receptor Antagonist
  • Neurokinin NK1 Receptor Antagonist
  • Others
Applications
  • CINV
  • PONV
  • Motion Sickness
  • Pregnancy
  • Others
Companies covered
  • Merck & Co. Inc.
  • Helsinn Group
  • Unimed Pharmaceuticals (AbbVie Inc.)
  • Kyowa Kirin
  • Sanofi
  • Qilu Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Taiji group
  • Novartis
  • Heron Therapeutics
  • Atnahs Pharma UK Limited
  • Mylan
  • Duchesnay
  • Tesaro

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nausea And Vomiting Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nausea And Vomiting Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nausea And Vomiting Treatment Market Dynamics
  1. 2.1 Nausea And Vomiting Treatment Industry Trends
  2. 2.2 Nausea And Vomiting Treatment Industry Drivers
  3. 2.3 Nausea And Vomiting Treatment Industry Opportunities and Challenges
  4. 2.4 Nausea And Vomiting Treatment Industry Restraints
3 Nausea And Vomiting Treatment Market by Company
  1. 3.1 Global Nausea And Vomiting Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Nausea And Vomiting Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Nausea And Vomiting Treatment Company Ranking (2024-2026)
  4. 3.4 Global Nausea And Vomiting Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Nausea And Vomiting Treatment Company Product Type and Application
  6. 3.6 Global Nausea And Vomiting Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nausea And Vomiting Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nausea And Vomiting Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nausea And Vomiting Treatment Market by Type
  1. 4.1 Nausea And Vomiting Treatment Type Introduction
  2. 4.1.1 Serotonin Receptor Antagonist
  3. 4.1.2 Neurokinin NK1 Receptor Antagonist
  4. 4.1.3 Others
  5. 4.2 Global Nausea And Vomiting Treatment Sales Value by Type
  6. 4.2.1 Global Nausea And Vomiting Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nausea And Vomiting Treatment Sales Value by Type (2021-2032)
  8. 4.2.3 Global Nausea And Vomiting Treatment Sales Value Share by Type (2021-2032)
5 Nausea And Vomiting Treatment Market by Application
  1. 5.1 Nausea And Vomiting Treatment Application Introduction
  2. 5.1.1 CINV
  3. 5.1.2 PONV
  4. 5.1.3 Motion Sickness
  5. 5.1.4 Pregnancy
  6. 5.1.5 Others
  7. 5.2 Global Nausea And Vomiting Treatment Sales Value by Application
  8. 5.2.1 Global Nausea And Vomiting Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Nausea And Vomiting Treatment Sales Value by Application (2021-2032)
  10. 5.2.3 Global Nausea And Vomiting Treatment Sales Value Share by Application (2021-2032)
6 Nausea And Vomiting Treatment Regional Value Analysis
  1. 6.1 Global Nausea And Vomiting Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nausea And Vomiting Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nausea And Vomiting Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nausea And Vomiting Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nausea And Vomiting Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Nausea And Vomiting Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nausea And Vomiting Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Nausea And Vomiting Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nausea And Vomiting Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nausea And Vomiting Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nausea And Vomiting Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Nausea And Vomiting Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nausea And Vomiting Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nausea And Vomiting Treatment Sales Value Share by Country, 2025 VS 2032
7 Nausea And Vomiting Treatment Country-level Value Analysis
  1. 7.1 Global Nausea And Vomiting Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nausea And Vomiting Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nausea And Vomiting Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nausea And Vomiting Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nausea And Vomiting Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nausea And Vomiting Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nausea And Vomiting Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co. Inc.
  2. 8.1.1 Merck & Co. Inc. Company Information
  3. 8.1.2 Merck & Co. Inc. Business Overview
  4. 8.1.3 Merck & Co. Inc. Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co. Inc. Nausea And Vomiting Treatment Product Portfolio
  6. 8.1.5 Merck & Co. Inc. Recent Developments
  7. 8.2 Helsinn Group
  8. 8.2.1 Helsinn Group Company Information
  9. 8.2.2 Helsinn Group Business Overview
  10. 8.2.3 Helsinn Group Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Helsinn Group Nausea And Vomiting Treatment Product Portfolio
  12. 8.2.5 Helsinn Group Recent Developments
  13. 8.3 Unimed Pharmaceuticals (AbbVie Inc.)
  14. 8.3.1 Unimed Pharmaceuticals (AbbVie Inc.) Company Information
  15. 8.3.2 Unimed Pharmaceuticals (AbbVie Inc.) Business Overview
  16. 8.3.3 Unimed Pharmaceuticals (AbbVie Inc.) Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Unimed Pharmaceuticals (AbbVie Inc.) Nausea And Vomiting Treatment Product Portfolio
  18. 8.3.5 Unimed Pharmaceuticals (AbbVie Inc.) Recent Developments
  19. 8.4 Kyowa Kirin
  20. 8.4.1 Kyowa Kirin Company Information
  21. 8.4.2 Kyowa Kirin Business Overview
  22. 8.4.3 Kyowa Kirin Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kyowa Kirin Nausea And Vomiting Treatment Product Portfolio
  24. 8.4.5 Kyowa Kirin Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Nausea And Vomiting Treatment Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Qilu Pharma
  32. 8.6.1 Qilu Pharma Company Information
  33. 8.6.2 Qilu Pharma Business Overview
  34. 8.6.3 Qilu Pharma Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Qilu Pharma Nausea And Vomiting Treatment Product Portfolio
  36. 8.6.5 Qilu Pharma Recent Developments
  37. 8.7 Teva Pharmaceutical Industries Ltd.
  38. 8.7.1 Teva Pharmaceutical Industries Ltd. Company Information
  39. 8.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
  40. 8.7.3 Teva Pharmaceutical Industries Ltd. Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Pharmaceutical Industries Ltd. Nausea And Vomiting Treatment Product Portfolio
  42. 8.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  43. 8.8 Taiji group
  44. 8.8.1 Taiji group Company Information
  45. 8.8.2 Taiji group Business Overview
  46. 8.8.3 Taiji group Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Taiji group Nausea And Vomiting Treatment Product Portfolio
  48. 8.8.5 Taiji group Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Nausea And Vomiting Treatment Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Heron Therapeutics
  56. 8.10.1 Heron Therapeutics Company Information
  57. 8.10.2 Heron Therapeutics Business Overview
  58. 8.10.3 Heron Therapeutics Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Heron Therapeutics Nausea And Vomiting Treatment Product Portfolio
  60. 8.10.5 Heron Therapeutics Recent Developments
  61. 8.11 Atnahs Pharma UK Limited
  62. 8.11.1 Atnahs Pharma UK Limited Company Information
  63. 8.11.2 Atnahs Pharma UK Limited Business Overview
  64. 8.11.3 Atnahs Pharma UK Limited Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Atnahs Pharma UK Limited Nausea And Vomiting Treatment Product Portfolio
  66. 8.11.5 Atnahs Pharma UK Limited Recent Developments
  67. 8.12 Mylan
  68. 8.12.1 Mylan Company Information
  69. 8.12.2 Mylan Business Overview
  70. 8.12.3 Mylan Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Mylan Nausea And Vomiting Treatment Product Portfolio
  72. 8.12.5 Mylan Recent Developments
  73. 8.13 Duchesnay
  74. 8.13.1 Duchesnay Company Information
  75. 8.13.2 Duchesnay Business Overview
  76. 8.13.3 Duchesnay Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Duchesnay Nausea And Vomiting Treatment Product Portfolio
  78. 8.13.5 Duchesnay Recent Developments
  79. 8.14 Tesaro
  80. 8.14.1 Tesaro Company Information
  81. 8.14.2 Tesaro Business Overview
  82. 8.14.3 Tesaro Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Tesaro Nausea And Vomiting Treatment Product Portfolio
  84. 8.14.5 Tesaro Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst